New drug cocktail aims to shrink melanoma before surgery

NCT ID NCT07586904

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether a combination of two drugs—cadonilimab and a high-dose interferon—can safely shrink tumors in people with stage III or IV melanoma before they have surgery. Ten participants will receive the drugs for three months, and researchers will monitor tumor response and side effects. The goal is to gather initial data to support larger future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Cadonilimab and recombinant human interferon α1b
What this could lead to
If successful, this could point toward a new pre-surgery treatment option for advanced melanoma that helps shrink tumors before surgery.
What could go wrong
This is a very early, small trial with only 10 participants, so results may not apply to everyone. The drug combination may cause side effects like fatigue or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA (SKIN CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Xijing Hospital, Air Force Medical University Xi'an, Shaanxi, China

    RECRUITING

    Xi'an, China

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.